Basic Information
Zimbus Breezhaler
Regulatory Information
EMEA/H/C/005518
Authorised
July 3, 2020
April 30, 2020
7
November 27, 2024
Company Information
Ireland
Vista Building Elm Park Merrion Road Dublin 4
NOVARTIS EUROPHARM LIMITED
Active Substances Detail
Glycopyrronium bromideIndacaterol (acetate)Mometasone furoate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Maintenance treatment of asthma in adults whose disease is not adequately controlled.
Overview Summary
Zimbus Breezhaler is an asthma medicine for inhalation. It is used for maintenance (regular) treatment in adults whose asthma is not controlled well enough with inhaled long-acting beta-2 agonist together with a high dose of an inhaled corticosteroid. It should be used for patients who have had at least one asthma attack (exacerbations) in the last year. Zimbus Breezhaler contains the active substances indacaterol, glycopyrronium bromide and mometasone.